Author + information
- Cheol Hyun Lee,
- Kyusup Lee,
- Jung Ae Hong,
- Do-Yoon Kang,
- Se Hun Kang,
- Pil Hyung Lee,
- Jung-Min Ahn,
- Duk-Woo Park,
- Seung-Whan Lee,
- Young-Hak Kim and
- Cheol Whan Lee
Background: Statin therapy is the standard treatment for atherosclerotic cardiovascular disease. However, the benefits of statin therapy in patients with vasospastic angina (VSA) remains unknown.
Objectives: This study investigated the long-term benefits of statin therapy in patients with VSA.
Methods: Between March 1996 and September 2014, a total of 1779 VSA patients were enrolled in the ASAN VSA Registry. The primary endpoint was defined as death from any cause at a median follow-up duration of 8.1 years (interquartile range: 4.3-11.6 years).
Results: Among the study patients, 839 patients (47.2%) were treated with statin therapy at enrollment. During the follow-up period, the statin therapy group demonstrated a lower incidence rate of death from any cause (0.67% patient-years vs 1.27% patient-years; adjusted hazard ratio [aHR] = 0.51; 95% confidence interval [CI] = 0.35-0.74; p < 0.001) and a lower incidence rate of cardiac death (0.07% patient-years vs 0.5% patient-years; aHR = 0.10; 95% CI = 0.03-0.32; p < 0.001).
Conclusions: Administering statin therapy to patients with VSA is associated with a lower mortality rate during long-term follow-up. Statin therapy should therefore be considered as the standard treatment on top of vasodilator therapy for the treatment of VSA.
Poster Hall, Hall C
Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Advances in Lipid Management
Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy
Presentation Number: 1203-311
- 2017 American College of Cardiology Foundation